CD274 and breast carcinoma: Previous single-arm meta-analysis have shown that the incidence of AEs ≥ grade 3 of PD-1/PD-L1 inhibitors was 34.62% in breast cancer (40), 13.4% in head and neck cancer (41), and 21% in lymphoma (42).